1. Izaguirre-Avila R, De la Pena-Diaz A, Barinagarrementeria-Aldatz F, et al. Effect of clopidogrel on platelet aggregation and plasma concentration of fibrinogen in subjects with cerebral or coronary atherosclerotic disease. Clin Appl Thromb Haemost2002;8:169-169.
2.
2. De Maat MP, Arnold AE, van Buuren S, et al. Modulation of plasma fibrinogen levels by ticlopidine in healthy volunteers and patients with stable angina pectoris. Thromb Haemost1996;76:166-166.
3.
3. De Maat MP. Effects of diet, and genes on plasma fibrinogen levels. Ann NY Acad Sci2001;936:509-509.
4.
4. Mikhailidis DP, Barradas MA, Maris A, et al. Fibrinogen-mediated activation of platelet aggregation and thromboxane A2 release: Pathological implications in vascular disease. J Clin Pathol1985;38:1166-1166.
5.
5. Mikhailidis DP, Barradas MA, Mier A, et al. Platelet function in patients admitted with a diagnosis of myocardial infarction. Angiology1987;38:36-36.
6.
6. Mikhailidis DP, Jeremy JY, Barradas MA, et al. The effect of ethanol on vascular prostacyclin synthesis, platelet aggregation and platelet thromboxane release. BMJ1983;287:1495-1495.
7.
7. Umemura K, Ishihara H, Nakashima M. Anti-platelet effects of clopidogrel in rat middle cerebral artery thrombosis model. Thromb Res1995;80:209-209.
8.
8. Yao SK, McNatt J, Cui K, et al. Combined ADP and thromboxane A2 antagonism prevents cyclic flow variations in stenosed and endothelium-injured arteries in non-human primates. Circulation1993;88:2888-2888.
9.
9. Hirata Y, Umemura K, Uematsu T, et al. An experimental myocardial infarction model in the rat and its properties. Jap J Pharmacol1995;67:51-51.
10.
10. Dale J, Myhre E, Rootwelt K. Effects of dipyridamole and acetylsalicylic acid on platelet functions in patients with aortic ball-valve prostheses. Am Heart J1975;89:613-613.
11.
11. Fuster V, Chesebro JH, Frye RL, et al. Platelet survival and the development of coronary artery disease in the young adult: Effects of cigarette smoking, strong family history and medical therapy. Circulation1981;63:546-546.
12.
12. Jagroop IA, Geroulakos G, Matsagas M, et al. The effect of clopidogrel (Plavix) function in patients with peripheral vascular disease-comparison with aspirin. First International symposium on cardiovascular science from bench to bedside, Hong Kong. J Cardiac Surg2002; in press.
13.
13. Blann AD, Lanza F, Galajda P, et al. Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis-the influence of aspirin and cigarette smoking. Thromb Haemost2001;86:777-777.
14.
14. Barradas MA, Stansby G, Hamilton G, et al. Diminished platelet yield and enhanced platelet aggregability in platelet rich plasma of peripheral vascular disease patients. Int Angiol1994;13:202-202.
15.
15. Barradas MA, O'Donoghue S, Mikhailidis DP. Measurement of platelet volume using a channelyzer: Assessment of the effect of agonists and antagonists. In vivo1992;6:629-629.
16.
16. Jagroop IA, Clatworthy I, Lewin J, et al. Shape change in human platelets: Measurement with a channelyzer and visualisation by electron microscopy. Platelets2000;11:28-28.
17.
17. Jagroop IA, Mikhailidis DP. An investigation of the serotonergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models. Platelets2000;11:156-156.
18.
18. Jagroop IA, Mikhailidis DP. Effect of endothelin-1 on human platelet shape change: Reversal of activation by naftidrofuryl. Platelets2000;11:272-272.
19.
19. Jagroop IA, Burnstock G, Mikhailidis DP. Both the ADP receptors, P2Y. and P2Y12, play a role in controlling shape change in humans platelets. Platelets2002; in press.
20.
20. Wilde JI, Retzer M, Siess S, et al. ADP-induced platelet shape change: An investigation of the signaling pathways involved and their dependence on he methods of platelet preparation. Platelets2000;11:286-286.
21.
21. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost2000;84:891-891.
